CDH3 and neoplasm: The impact of P-cadherin overexpression in cancer is still controversial, as this molecule seems to act as tumour-promoting and a marker of a bad prognosis in several cancer types—namely, in breast, glioblastoma, and gastric cancer [36]—but may also act as a marker of a good prognosis—namely, in colon cancer [37].